Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis

Strategy analysis


  • Sort by Price
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products descending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Chronic Migraine Survey

    $599.00

    Datamonitor conducted a 5-question survey of 26 United States and 25 European (based in France, Germany, Italy, Spain and United Kingdom) neurologists involved in pain management to gauge current prescribing practices in prophylactic treatment of chronic migraine and potential future use of the calcitonin gene-related peptide (CGRP) receptor targeting monoclonal antibody (mAb) AMG 334 (AMGN) and CGRP targeting mAbs ALD403 (ALDR) and TEV-48125 (TEVA).

    March 9, 2017
    Find out more
  • Non-Alcoholic Steatohepatitis (NASH) Survey

    Non-Alcoholic Steatohepatitis (NASH) Survey

    $599.00

    Datamonitor conducted a 4-question survey of 42 United States and 40 European (based in France, Germany, Italy and United Kingdom) gastroenterologists to gauge their views on late-stage clinical candidates in non-alcoholic steatohepatitis (NASH), including Ocaliva (ICPT), elafibranor (GNFTF) and selonsertib (GILD), and their projected use of these drugs if FDA-approved.

    March 9, 2017
    Find out more

  • Datamonitor Axial Spondyloarthritis KOL Interviews

    $599.00

    Datamonitor interviewed three arthritis specialists, one based each in France, Italy and the US, to gauge their views on currently available treatment options, pipeline drugs, biosimilars and treatment challenges in axial spondyloarthritis (axSpA). The three interviews were combined into a single report.

    March 9, 2017
    Find out more

  • Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

    $599.00

    Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.

    March 9, 2017
    Find out more
  • Opioids and Chronic Neuropathic Pain Management KOL Interview

    Opioids and Chronic Neuropathic Pain Management KOL Interview

    $599.00

    Biomedtracker interviewed a neurologist based in the United States who currently treats over 1000 patients with chronic neuropathic pain per year to determine his current treatment practices for indications including fibromyalgia and views on the use of opioids and abuse-deterrent opioids.

    March 9, 2017
    Find out more
  • Chronic Neuropathic Pain Survey

    Chronic Neuropathic Pain KOL Survey

    $599.00

    Biomedtracker performed a 5-question survey of 30 United States neurologists who currently treat patients with chronic neuropathic pain and prescribe opioids to at least some of their patients with chronic neuropathic pain to gauge current use of adjuvants (TCAs, anti-convulsants, SNRIs, SSRIs, and NMDA receptor antagonists) and potential future use of cebranopadol and raxatrigine to treat chronic neuropathic pain.

    March 9, 2017
    Find out more
  • Abuse-Deterrent Opioids Survey

    Abuse-Deterrent Opioids Survey KOL Interview

    $599.00

    Biomedtracker performed a 5-question survey of 30 United States primary care physicians who currently treat patients with chronic pain and prescribe opioids to at least some of their patients with chronic pain to gauge current and future use of abuse-deterrent opioids to treat chronic pain.

    March 9, 2017
    Find out more
  • Non-Small Cell Lung Cancer KOL Interview

    Non-Small Cell Lung Cancer KOL Interview

    $599.00

    Biomedtracker interviewed a lung cancer specialist based in the US to determine his views on the non-small cell lung cancer treatment landscape, with a focus on PD-1 immunotherapies.

    December 16, 2016
    Find out more

  • Datamonitor Psoriatic Arthritis KOL Interviews

    $599.00

    Datamonitor interviewed three rheumatologists, two based in the US and one in the UK, to determine their current treatment practices and views on pipeline and marketed drugs for psoriatic arthritis. The three interviews were combined into a single report.

    December 12, 2016
    Find out more

  • Ovarian Cancer Pulse Survey

    $599.00

    Diagnostics/diagnostic techniques discussed:

    etarfolatide/folic acid, BRCA mutation testing

    May 7, 2014
    Find out more

  • Post-EASL KOL Insight Interview

    $599.00

    The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in
    London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and
    soon-to-be approved, direct-acting antivirals for Hepatitis C.

     

    May 6, 2014
    Find out more

  • Seizure Pulse Survey

    $599.00

    Eslicarbazepine has been approved in ex-US markets including the EU for years.

    We surveyed 10 US Neurologists to determine prelaunch perceptions of Aptiom.

    March 25, 2014
    Find out more

  • Breast Cancer KOL Insight Interview

    $599.00

    Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent
    change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.

    May 8, 2014
    Find out more

  • Post-AAIC KOL Interview

    $599.00

    Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.

    August 6, 2014
    Find out more

  • Psychiatry KOL Insight Interview

    $599.00

    At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)

    January 24, 2014
    Find out more
Page 19 of 24
Page 19 of 24«‹1718192021›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top